Quarterly report [Sections 13 or 15(d)]

Segment Information

v3.25.1
Segment Information
 3 Months Ended
Mar. 31, 2025
Segment Reporting [Abstract]  
Segment Information Segment Information
The Company has identified two operating segments, diagnostic services and consumer products, based on the manner in which the Company’s CEO, as Chief Operating Decision Maker, assesses performance and allocates resources across the organization. The operating segments are organized in a manner that depicts the difference in revenue generating synergies that include the separate processes, profit generation and growth of each segment. The diagnostic services segment provides diagnostic information services to a broad range of customers in the United States, including health plans, third party payers and government organizations. The consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provides personal genomics products and services. The unallocated corporate expenses mainly included professional fees associated with the public company.
The following table is a summary of segment information for three months ended March 31, 2025 and 2024 (amounts in thousands):
For the three months ended
March 31, 2025 March 31, 2024
Net revenues
Diagnostic services $ —  $ — 
Consumer products 1,431  2,356 
Consolidated net revenue 1,431  2,356 
Cost of revenue
Diagnostic services 232  720 
Consumer products 673  1,696 
Consolidated cost of revenue 905  2,416 
Depreciation and amortization expense
Diagnostic services 334  801 
Consumer products 807  804 
Total Depreciation and amortization expense 1,141  1,605 
Operating and other expenses
Diagnostic services 168  1,824 
Consumer products 1,061  1,115 
Unallocated corporate 2,834  3,486 
Total operating and other expenses 4,063  6,425 
Income (loss) from operations, before income taxes
Diagnostic services (734) (3,345)
Consumer products (1,110) (1,259)
Unallocated corporate (2,834) (3,486)
Total loss from operations, before income taxes (4,678) (8,090)
Income tax (expense) benefit —  2,566 
Total loss from operations, after income taxes (4,678) (5,524)
Net loss from continuing operations $ (4,678) $ (5,524)
The following table is a summary of segment information as of March 31, 2025 and December 31, 2024 (amounts in thousands):
March 31, 2025 December 31, 2024
ASSETS
Diagnostic services $ 25,516  $ 26,069 
Consumer products 18,712  19,745 
Unallocated corporate 5,883  5,804 
Assets in discontinued operations —  11,582 
Total assets $ 50,111  $ 63,200